Sensei Biotherapeutics, Inc. SNSE · Stock Open Sensei Biotherapeutics, Inc. in new tab
Sensei Biotherapeutics, Inc. Analysis (SNSE)
Is Sensei Biotherapeutics, Inc. a good investment? Sensei Biotherapeutics, Inc. (SNSE) is currently trading at 13.85 USD. Market analysts have a consensus price target of 51.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Sensei Biotherapeutics, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is -3.97.
Investor FAQ
Does Sensei Biotherapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Sensei Biotherapeutics, Inc.?
Sensei Biotherapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -142.72.
Company Profile
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
| Split Date | Split Ratio to 1 |
|---|---|
| June 17, 2025 | 0.050000 |
Community Discussion